Global Next Generation Sequencing Services Market Size Likely to Grow at a CAGR of 23.5% By 2035

The market size of the global next generation sequencing services will be estimated at USD 6.8 billion in 2025 and is expected to grow to between USD 8.3 billion in 2026 and about USD 56.1 billion by 2035 with a current CAGR of 23.5% during the period of 2026 to 2035.

Next Generation Sequencing Services Market Revenue and Trends

Next generation sequencing services are laboratory and analytical outsourcing, which utilize high-throughput DNA and RNA sequencing technologies to efficiently perform genetic analysis on a large scale. Normally, these services will have the different components of the whole process - sample preparation, sequencing, bioinformatics, data interpretation, and finally reporting - with providers specializing in it delivering the service to customers who, for reasons of resources or lack of expertise, are not able to do in-house sequencing.

NGS services have already found their applications in genomics, whole-genome and whole-exome sequencing, targeted gene panels, transcriptomics, metagenomics, epigenetic analysis, etc. across research, clinical diagnostics, pharmaceutical and biotechnology development, agriculture, and public health sectors. This, in turn, gives rise to precise medicine, drug discovery, disease surveillance, and large-scale genomics research, with NGS services facilitating them through quicker turnaround times, lower costs, and access to sophisticated analytical capabilities.

What are the Factors That Have a Significant Contribution to the Growth of the Next Generation Sequencing Services Market?

It is undeniable that the drug development and pharma/biotech outsourcing have a significant impact on the expansion of the next generation sequencing services market. Data genomics is the core of the modern drug discovery and development processes. The pharmaceutical and biotech industries are very dependent on NGS technology during the whole process of drug development, from the very first step of identifying the right drug target to conducting clinical trials and monitoring. All these activities will typically require large amounts of samples to be tested, and the data produced will be so complex that the in-house sequencing will be too expensive and inconvenient.

The good news is that the drug and biotech companies are already looking to the specialized NGS service providers for the solution. These companies provide high-throughput platforms, approved workflows, and bioinformatics capability all integrated together. Plus, outsourcing helps in the reduction of capital expenditure that would have been incurred due to the buying and maintaining of advanced sequencing instruments, employing of skilled bioinformatics personnel, and managing of data infrastructures on a large scale. Moreover, it provides the companies with quick access to a large throughput of sequencing dependent on their needs, which is of prime importance during the multicenter clinical investigations and the latter phases of drug development.

Additionally, the rising clinical adoption is the main driving force of the next-generation sequencing services market, as NGS is being widely accepted in routine clinical practice for diseases like cancer, rare genetic defects, infertility, and infectious disease testing. NGS is considered accurate and cost-effective in providing detailed genetic information through single-test applications like tumor profiling, liquid biopsy, carrier screening, and pathogen identification; thus, hospitals and diagnostic labs are using these tests. Nevertheless, the high price of sequencing equipment, strict quality standards, and the requirement of having bioinformatics expertise are pushing many medical institutions to outsource their testing to professional NGS service providers. The increase in the use of outsourced NGS services, already significantly contributing to market growth, is further supported by the development of clinical guidelines, regulatory approvals, and reimbursement frameworks that favor genomics-based diagnostics.

Segment Insight

By Workflow

The sequencing segment held the largest market share of over 52% in 2025. The large percentage of the market share can be attributed to different faith and scientific efforts by companies to improve the use of sequencing services. For example, in June 2025, The Jackson Laboratory's Advanced Precision Medicine Laboratory in Farmington, Connecticut, USA, adopted a complete automatic NGS workflow powered by Illumina, which included in-house sample tracking, analysis, and variant interpretation. These organizations provide a variety of NGS services to cater to different types of samples. The firm produces publication-ready data that will help customer research programs in various areas like agriculture, medicine, and environmental science to get success.

Regional Insights

North America held the highest market share in 2025. The growing technological advancements in the area and presence of the major players in the area drive the market growth. Also, the favorable government initiatives flourish the industry growth.

Besides, the Asia Pacific market has the highest rate of growth in the next generation sequencing services market. The increasing expenditure in healthcare infrastructure and growing prevalence of various diseases like cancer, CVD and others.

Report Scope

Recent Developments

• In June 2025, the signing of an MOU has opened doors for a revolutionary partnership between Gene Solutions, a dominant force in the global biotechnological landscape, and Shenzhen USK Bioscience Co., Ltd. (USKBio), a respected innovator in the field of molecular diagnostics. The deal that has been made between the two entities is unmatched in the industry and will result in the setting up of an ultra-modern next-generation sequencing (NGS) lab in southern China, thus making a great leap forward in the local cancer diagnosis. (Source: https://www.prnewswire.com/apac/news-releases/gene-solutions-and-shenzhen-usk-bioscience-forge-strategic-partnership-to-establish-next-generation-sequencing-laboratory-in-southern-china-302481630.html)

List of the prominent players in the Next Generation Sequencing Services Market:

• Illumina Inc.

• Thermo Fisher Scientific

• Oxford Nanopore Technologies

• Pacific Biosciences of California Inc.

• QIAGEN N.V.

• Genedata

• Roche Sequencing Solutions

• Agilent Technologies

• PerkinElmer Inc.

• Bio-Rad Laboratories Inc.

• BGI Group

• Genomics PLC

• MGI Tech

• Roche NimbleGen

• Macrogen Inc.

• Novogene Corporation

• GATC Biotech AG

• BaseClear B.V.

• Dovetail Genomics

• Fasteris SA

• Others

The Next Generation Sequencing Services Market is segmented as follows:

By Service Type

• Human Genome Sequencing Services

• Microbial Genome-based Sequencing Services

• Single Cell Sequencing Services

• Gene Regulation Services

• Animal & Plant Sequencing Services

• Other Sequencing Services

By Workflow

• Pre-sequencing

• Data Analysis

• Sequencing

By End Use

• Universities & Other Research Entities

• Pharma & Biotech Entities

• Hospitals & Clinics

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America